Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
Is once-weekly insulin a viable alternative for type 2 diabetes? A meta-analysis of randomized controlled trials
M Richardson1, Bikash Ranjan Meher1, Monalisa Jena1
1Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Aims:
Once-weekly novel insulin preparations such as Icodec and basal insulin Fc (BIF)/insulin Efsitora Alfa have raised hope among clinicians and patients when they were developed and evaluated in a series of clinical trials. However, there were conflicting results regarding their efficacy and safety. This meta-analysis was carried out to evaluate the efficacy and safety of once-weekly insulin in patients with Type 2 diabetes mellitus (T2DM).
Methods:
PubMed/MEDLINE, Cochrane database, Scopus, and WHO International Clinical Trials Registry Platform (ICTRP) were searched till November 2024 for randomized controlled trials (RCTs). Our literature search found 2759 articles, out of which 11 studies with 11 reports were included in the meta-analysis as per eligibility criteria.
Results:
5799 participants from 11 RCTs were included. Once-weekly insulin showed significant reduction of HbA1c, and pooled mean difference of once-weekly insulin vs once-daily insulin was - 0.09 (95% CI - 0.16 to - 0.02). Subgroup analysis revealed that Icodec - 0.12 (95% CI - 0.20 to - 0.04) was found to be superior, whereas BIF was found to be non-inferior 0.01 (95% CI - 0.11 to 0.13) compared to once-daily insulin regimen in reduction of HbA1c in T2DM. No significant differences were observed between once-weekly and once-daily insulin for other safety outcomes.
Conclusions:
Once-weekly insulin regimen was superior in reducing HbA1c level while maintaining a similar safety profile to the once-daily insulin regimen, thus suggesting that such regimen may potentially be an alternative to the currently established once-daily basal insulin regimen.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...

